Autolus Therapeutics Plc (AUTL)
1.78
-0.07
(-3.78%)
USD |
NASDAQ |
Oct 02, 16:00
1.775
0.00 (0.00%)
After-Hours: 20:00
Autolus Therapeutics Gross Profit Margin (Quarterly) : 55.20% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 55.20% |
| March 31, 2026 | 6.29% |
| December 31, 2025 | -4.29% |
| September 30, 2025 | -51.21% |
| June 30, 2025 | -28.15% |
| March 31, 2025 | -125.2% |
| December 31, 2024 | -46.38K% |
| September 30, 2024 | |
| June 30, 2024 | |
| March 31, 2024 | 82.10% |
| Date | Value |
|---|---|
| December 31, 2023 | |
| September 30, 2023 | -239.7% |
| June 30, 2023 | |
| March 31, 2023 | -46.98% |
| December 31, 2022 | 55.19% |
| September 30, 2022 | 0.00% |
| June 30, 2022 | |
| March 31, 2022 | |
| December 31, 2021 | 0.00% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Bicycle Therapeutics Plc | -69.64% |
| argenx SE | -- |
| Evaxion AS | -- |
| DBV Technologies SA | -- |
| Cellectis SA | 15.62% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -143.5% |
| Return on Assets | -46.70% |
| Return on Invested Capital | -51.71% |
| Profit Margin (Quarterly) | -85.60% |
| Operating Margin (Quarterly) | -95.95% |
| Return on Net Operating Assets | -123.0% |